Osaka, Japan

Eiji Kawanishi

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 59(Granted Patents)


Location History:

  • Kitamoto, JP (2011 - 2014)
  • Osaka, JP (2011 - 2021)

Company Filing History:


Years Active: 2011-2021

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Eiji Kawanishi: Innovator in Pharmaceutical Chemistry

Introduction

Eiji Kawanishi is a prominent inventor based in Osaka, Japan, known for his significant contributions to pharmaceutical chemistry. With a total of eight patents to his name, he has made remarkable advancements in the field, particularly in the development of innovative compounds and methods.

Latest Patents

Kawanishi's latest patents include groundbreaking work on bridged nucleic acid GuNA, which outlines a method for producing the same and an intermediate compound. This method involves a step of reacting a compound represented by a specific formula with a reducing agent to cleave an oxazolidine ring fused to a cycle A'. The reducing agent utilized in this process includes phosphines, metal hydrides, or transition metal catalysts in the presence of hydrogen gas. Another notable patent focuses on pyrazolopyrimidine compounds and their use as PDE10 inhibitors, showcasing his expertise in creating compounds with therapeutic potential.

Career Highlights

Throughout his career, Eiji Kawanishi has worked with esteemed organizations such as Mitsubishi Tanabe Pharma Corporation and Osaka University. His work in these institutions has allowed him to push the boundaries of pharmaceutical research and development.

Collaborations

Kawanishi has collaborated with notable colleagues, including Sumihiro Nomura and Kiichiro Ueta, further enhancing his research and innovation efforts.

Conclusion

Eiji Kawanishi's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a leading inventor in the field. His innovative approaches continue to influence the development of new therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…